Latest Conference Articles

The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.

Priscilla Tsondai, MD, MPH, breaks down top care gaps as opportunities for care improvement.

Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.

Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.

The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.

Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute to design and test novel delivery models for HIV services.

These abstracts highlight the compounded challenges people with HIV face.

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.

Michelle Hessen, OD, spoke about the results of a new study evaluating the efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye.

Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.

Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples living in Kenya.

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.

Artificial intelligence (AI) is emerging as a tool that can improve patient outcomes and provider care efficiency, says Douglas Flora, MD, FACCC, of St. Elizabeth Healthcare.

Patients in Washington, DC, and San Francisco had minimal early uptake and adherence to doxycycline postexposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.

When patients switched to either fostemsavir or the combination of dolutegravir/lamivudine (DTG/3TC), suppression was maintained in most patients.

Bridgette J. Picou, LVN, ACLPN, presented research on the lived experiences of women living with HIV and going through menopause on Tuesday, during the mini symposia, “Hot Topic: Menopause and HIV.”

Long-term effects of COVID-19 include lingering symptoms that take months to improve, more severe illness for cancer survivors, and a higher risk of death after infection for people living in rural areas.

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in infants, explains Priscilla Tsondai, MD, MPH, and unlike adults they require age-appropriate formulations, caregiver support, and strategies to ensure adherence.

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and user-friendly diagnostic methods are key.

This research investigated averted hospitalizations in Oregon and Washington, which had greater than 75% uptake of at least 1 dose of an mRNA-based COVID vaccine.

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but requires methods of improving adherence to follow-up.

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.

Steven Daniel Daveluy, MD, FAAD, advocates for dermatologists to adopt cultural humility, engage in continuous education, and navigate ethical considerations to provide equitable and supportive care to LGBTQ patients.

This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.

Experts stressed the importance of dermatologists engaging in climate advocacy and adopting sustainable practices, as their actions may inspire others to follow suit.

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ruxolitinib for itch and inflammation, while also outlining a comprehensive approach to chronic pruritus management.

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, advocates for teledermatology as a vital tool to enhance health care equity by improving access for underserved populations and reducing physician burnout.

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing the balance between treatment efficacy and safety.